Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCND2 | P30279 | 1/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712289 | 1.00 | BRD4 (0.50) | BRD4BRPF1CA12CA9KAT2B | |
| SCHEMBL3515138 | 0.77 | DAO (0.47) | BRD4BRPF1CA12CA9KAT2B | |
| SCHEMBL27254155 | 0.77 | PARP1 (0.42) | BRD4BRPF1CA12CA9KAT2B | |
| SCHEMBL25723262 | 0.77 | CYP2C19 (0.42) | CDC7CDK2PARP1MTNR1AKDM4E | |
| SCHEMBL9577060 | 0.77 | PARP1 (0.46) | CDC7CDK2PARP1MTNR1AKDM4E | |
| SCHEMBL29311510 | 0.77 | PARP1 (0.42) | CDC7CDK2PARP1MTNR1AKDM4E | |
| SCHEMBL809908 | 0.77 | LMNA (0.50) | BRD4BRPF1CA12CA9KAT2B | |
| SCHEMBL27250199 | 0.77 | CDK4 (0.49) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL1376936 | 0.74 | CDK4 (0.54) | CDK4CCND1CCND2CCND3MTNR1A | |
| SCHEMBL11562270 | 0.74 | KDM4E (0.49) | KAT2BCDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4234389-A | — | — | None | — | — | JP | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| EP-4065586-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022184116-A1 | NEW SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏先声药业有限公司 | 2022-09-09 | — | — | WO | disclosed |
| WO-2021105072-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-03 | — | — | WO | disclosed |
| US-8809360-B2 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8809360-B2 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-1804797-B1 | USE OF A PYRIDINE COMPOUND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF SKIN LESIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| EP-1682550-B1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090069307-A1 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069307-A1 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| WO-2006046774-A1 | USE OF A PYRIDINE COMPOUND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF SKIN LESIONS | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-04 | — | — | WO | disclosed |
| JP-H04234389-A | NAPHTHYRIDINE DERIVATIVE AND ANTIULCER AGENT CONTAINING THE DERIVATIVE AS ACTIVE COMPONENT | SAPPORO BREWERIES LTD | 1992-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | SALL4, GLI2, GLI1 | BRD4 157/4885BRPF1 1027/4885CA12 2841/4885 |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | BRD4 784/4885BRPF1 1119/4885CA12 2207/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | BRD4 989/4885BRPF1 1509/4885CA12 2180/4885 |
| US-20090069307-A1 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions | NQO1, TYR, NDUFB7 | BRD4 228/4885BRPF1 1613/4885CA12 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.